Novartis Yönetim

Yönetim kriter kontrolleri 3/4

Novartis CEO'su Vas Narasimhan, Feb2018 tarihinde atandı, in görev süresi 7.25 yıldır. in toplam yıllık tazminatı $ 15.64M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.1% maaş ve 86.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.022% ine doğrudan sahiptir ve bu hisseler CHF 38.95M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 5.3 yıldır.

Anahtar bilgiler

Vas Narasimhan

İcra Kurulu Başkanı

US$15.6m

Toplam tazminat

CEO maaş yüzdesi	13.1%
CEO görev süresi	7.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Shareholders Will Probably Hold Off On Increasing Novartis AG's (VTX:NOVN) CEO Compensation For The Time Being

Feb 28

Recent updates

Novartis' (VTX:NOVN) Performance Is Even Better Than Its Earnings Suggest

May 07

Earnings Beat: Novartis AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 02

Novartis (VTX:NOVN) Seems To Use Debt Rather Sparingly

Mar 27

Novartis (VTX:NOVN) Has Announced That It Will Be Increasing Its Dividend To $3.50

Mar 04

Shareholders Will Probably Hold Off On Increasing Novartis AG's (VTX:NOVN) CEO Compensation For The Time Being

Feb 28

CEO Tazminat Analizi

Vas Narasimhan'un ücretlendirmesi Novartis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	US$13b
Dec 31 2024	US$16m	US$2m	US$12b
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$10b
Mar 31 2024	n/a	n/a	US$9b
Dec 31 2023	US$16m	US$2m	US$9b
Sep 30 2023	n/a	n/a	US$7b
Jun 30 2023	n/a	n/a	US$7b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$12m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$21b
Jun 30 2022	n/a	n/a	US$22b
Mar 31 2022	n/a	n/a	US$24b
Dec 31 2021	US$12m	US$2m	US$23b
Sep 30 2021	n/a	n/a	US$10b
Jun 30 2021	n/a	n/a	US$9b
Mar 31 2021	n/a	n/a	US$8b
Dec 31 2020	US$12m	US$2m	US$8b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$7b
Dec 31 2019	US$12m	US$2m	US$7b
Sep 30 2019	n/a	n/a	US$7b
Jun 30 2019	n/a	n/a	US$7b
Mar 31 2019	n/a	n/a	US$13b
Dec 31 2018	US$10m	US$2m	US$13b

Tazminat ve Piyasa: Vas 'nin toplam tazminatı ($USD 15.64M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.07M ).

Tazminat ve Kazançlar: Vas 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Vas Narasimhan (48 yo)

7.3yrs

Görev süresi

US$15,637,188

Tazminat

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vasant Narasimhan	Chief Executive Officer	7.3yrs	US$15.64m	0.022% CHF 39.0m
Harry Kirsch	Chief Financial Officer	12yrs	US$6.91m	0.023% CHF 40.4m
Victor Bulto	President of US	3.1yrs	US$6.36m	0.0018% CHF 3.2m
Patrick Horber	President of International	1.4yrs	US$6.49m	0.0032% CHF 5.7m
Steffen Lang	President of Operations	3.1yrs	US$4.17m	0.0063% CHF 11.2m
Paul Penepent	Head of Group Financial Reporting and Accounting	no data	Veri yok	Veri yok
Sloan Simpson	Global Head of Investor Relations	1.1yrs	Veri yok	Veri yok
Karen Hale	Chief Legal & Compliance Officer	4yrs	US$4.16m	0.0030% CHF 5.3m
Robert Kowalski	Chief People & Organization Officer	3.7yrs	US$3.45m	0.0011% CHF 2.0m
Linda Armstrong	Global Head of Respiratory Development	no data	Veri yok	Veri yok
David Soergel	Head of the Cardiovascular	no data	Veri yok	Veri yok
Evan Beckman	Global Head of Translational Medicine at Novartis Institute for BioMedical Research	no data	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: NOVN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Simon Moroney	Independent Vice Chairman of the Board	5.3yrs	US$506.95k	0.00040% CHF 712.5k
Daniel Vasella	Honorary Chairman	no data	US$3.34m	Veri yok
Bridgette Heller	Independent Non-Executive Director	5.3yrs	US$473.89k	0.00040% CHF 712.5k
François van Houten	Independent Non-Executive Director	8.3yrs	US$429.80k	0.00096% CHF 1.7m
Ton Buechner	Independent Non-Executive Director	9.3yrs	US$468.02k	0.0013% CHF 2.4m
Ana de Pro Gonzalo	Independent Non-Executive Director	3.2yrs	US$429.80k	0.00020% CHF 356.2k
Giovanni Caforio	Chairman of the Board	less than a year	Veri yok	Veri yok
Patrice Bula	Lead Independent Director	6.3yrs	US$456.02k	0.00068% CHF 1.2m
Daniel Hochstrasser	Independent Director	3.2yrs	US$434.96k	0.00025% CHF 445.3k
John Young	Non-Executive Independent Director	2.2yrs	US$424.29k	0.00011% CHF 195.9k
Nancy Andrews	Independent Non-Executive Director	10.3yrs	US$396.74k	0.00061% CHF 1.1m
Elizabeth Doherty	Independent Non-Executive Director	9.3yrs	US$495.93k	0.00085% CHF 1.5m

5.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NOVN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/11 13:35
Gün Sonu Hisse Fiyatı	2025/05/09 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Novartis AG 69 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Fabrizio Spagna	Axia Financial Research

Novartis Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Novartis Announces Executive Changes

Shareholders Will Probably Hold Off On Increasing Novartis AG's (VTX:NOVN) CEO Compensation For The Time Being

Novartis AG, Annual General Meeting, Mar 07, 2025

Recent updates

Novartis' (VTX:NOVN) Performance Is Even Better Than Its Earnings Suggest

Earnings Beat: Novartis AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Novartis AG (SWX:NOVN) entered into an agreement and plan of merger to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $470 million.

New minor risk - Financial position

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Novartis AG (SWX:NOVN) completed the acquisition of an unknown majority stake in Anthos Therapeutics, Inc. from Blackstone Life Sciences.

Novartis Receives FDA Accelerated Approval for Vanrafia (Atrasentan) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy

Market Volatility Derails Novartis' Plan to Sell Stake in its India Arm

Novartis Announces Executive Changes

Fda Approves Novartis Radioligand Therapy Pluvicto for Early Use Before Chemotherapy in Psma-Positive Metastatic Castration-Resistant Prostate Cancer

Novartis (VTX:NOVN) Seems To Use Debt Rather Sparingly

New Novartis Phase III Data Demonstrates Meaningful Efficacy and Safety Results of Intriathecal Onasemnogeneabeparvovec in Broad Patient Population with SMA

Novartis AG Approves Dividend for 2024, Payable from March 13, 2025

Novartis (VTX:NOVN) Has Announced That It Will Be Increasing Its Dividend To $3.50

Upcoming dividend of CHF3.50 per share

Novartis Oral Fabhalta (Iptacopan) Receives Positive CHMP Opinion for the Treatment of Adults Living with C3 Glomerulopathy (C3g)

Shareholders Will Probably Hold Off On Increasing Novartis AG's (VTX:NOVN) CEO Compensation For The Time Being

Novartis AG (SWX:NOVN) agreed to acquire an unknown majority stake in Anthos Therapeutics, Inc. from Blackstone Life Sciences for approximately $3.1 billion.

Strong Pipeline With Scemblix And Kisqali Will Strengthen Future Prospects

Novartis (VTX:NOVN) Is Increasing Its Dividend To $3.50

Dividend of CHF3.50 announced

Full year 2024 earnings: EPS exceeds analyst expectations

Novartis AG to Report Q2, 2025 Results on Jul 17, 2025

Novartis Announces Positive Topline Results from the Phase III Steer Study

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®? (ribociclib)

Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix (asciminib)

Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta

Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion.

New minor risk - Earnings quality

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis Receives Positive CHMP Opinion for Kisqali to Help Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Final dividend of CHF3.30 announced

New minor risk - Earnings quality

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG Proposes Dividend

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH